Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07479381 · ClinicalTrials.gov registry record
Colorectal Lesion Evaluation and Appropriate Resolution (CLEAR) Study
A clinical trial, sponsored by Harbinger Health.
- Terminated
- Registry status
- 14
- Enrollment target
NCT07479381: Clinical Trial study, sponsored by Harbinger Health.
NCT07479381 is a clinical trial that was terminated before completion, run by Harbinger Health. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07479381 was terminated before completion, sponsored by Harbinger Health.
- TERMINATED
- Registry status
- 14 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate a blood-based screening test for Colorectal Cancer (CRC).
Primary Outcome
1\. Establish the predictive value of the Harbinger test for colorectal cancer (CRC) per test readout category.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2026-03-20 |
| Est. Completion | 2026-03-27 |
Why NCT07479381 stopped before completion
NCT07479381 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT07479381 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07479381 about?
NCT07479381 is a clinical study titled "Colorectal Lesion Evaluation and Appropriate Resolution (CLEAR) Study". The primary objective of this study is to evaluate a blood-based screening test for Colorectal Cancer (CRC).
What is the current status of trial NCT07479381?
This trial is currently terminated. The enrollment target is 14 participants. The study started on 2026-03-20. Estimated completion is 2026-03-27.
Who is sponsoring clinical trial NCT07479381?
This trial is sponsored by Harbinger Health, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy